Get the Stockscreener App
2.3899
21.00%
0.3899
Onkure Therapeutics Inc stock is traded at $2.3899, with a volume of 251.32K.
It is up +21.00% in the last 24 hours and down -3.20% over the past month.
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.
See More
Previous Close:
$2.00
Open:
$2.19
24h Volume:
251.32K
Relative Volume:
1.65
Market Cap:
$29.62M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+18.62%
1M Performance:
-3.20%
6M Performance:
-57.02%
1Y Performance:
+0.00%
1-Day Range:
$2.185
$2.44
1-Week Range:
$1.91
$2.44
52-Week Range:
$1.70
$19.40
Onkure Therapeutics Inc Stock (OKUR) Company Profile
Name
Onkure Therapeutics Inc
Sector
Industry
Phone
(720) 307-2892
Address
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Compare OKUR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OKUR
Onkure Therapeutics Inc
|
2.31 | 27.43M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.94 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.65 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.06 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
638.10 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
299.89 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-30-25 | Initiated | Evercore ISI | Outperform |
| Dec-05-24 | Initiated | Leerink Partners | Outperform |
| Oct-10-24 | Initiated | Oppenheimer | Outperform |
| Dec-15-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-15-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-14-23 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-14-23 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Dec-14-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-14-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-14-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-15-23 | Initiated | William Blair | Outperform |
| Aug-28-23 | Initiated | H.C. Wainwright | Buy |
| Jul-03-23 | Initiated | BofA Securities | Buy |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Jan-27-22 | Initiated | Robert W. Baird | Outperform |
| Dec-21-21 | Initiated | H.C. Wainwright | Buy |
| Nov-22-21 | Initiated | Ladenburg Thalmann | Buy |
| May-04-21 | Initiated | Jefferies | Buy |
| May-04-21 | Initiated | Piper Sandler | Overweight |
| May-04-21 | Initiated | SVB Leerink | Outperform |
View All
Onkure Therapeutics Inc Stock (OKUR) Latest News
OnKure Therapeutics Advances Cancer Drug Development - TipRanks
What makes OnKure Therapeutics Inc. stock price move sharplyWeekly Profit Summary & Free Weekly Chart Analysis and Trade Guides - Newser
Using data models to predict OnKure Therapeutics Inc. stock movementTake Profit & Capital Efficiency Focused Ideas - Newser
Will OnKure Therapeutics Inc. stock recover after recent drop2025 Big Picture & Accurate Entry and Exit Point Alerts - Newser
Onkure Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update - GlobeNewswire
How sentiment analysis helps forecast OnKure Therapeutics Inc.Free Access to Real-Time Trade Insights - Newser
How to monitor OnKure Therapeutics Inc. with trend dashboardsLow Risk High Confidence Watchlist Builder - Newser
Applying big data sentiment scoring on OnKure Therapeutics Inc.Daily Investment Ideas with Market Insight - Newser
Price momentum metrics for OnKure Therapeutics Inc. explainedLong-Term Safety Investment Analysis Report - Newser
OnKure Therapeutics Inc. stock outlook for YEARReal Time Growth Signal with Smart Setup - Newser
OnKure Therapeutics (OKUR) to Release Earnings on Tuesday - Defense World
Is OnKure Therapeutics Inc. Stock a Good Fit for Conservative InvestorsDay Trading Setup Forecast with Trend Model - Newser
OnKure Therapeutics Inc. stock trend forecastQuarterly Investment Outlook and Key Summary - Newser
Using data filters to optimize entry into OnKure Therapeutics Inc.Entry Zone Watchlist With Momentum Focus - Newser
Why OnKure Therapeutics Inc. stock attracts strong analyst attentionFree Scalable Portfolio Growth Suggestions - Newser
How many analysts rate OnKure Therapeutics Inc. as a “Buy”Get ahead with breakthrough trading ideas - Jammu Links News
What is OnKure Therapeutics Inc. company’s growth strategyFree Buy/Sell Signal Notifications - Jammu Links News
What drives OnKure Therapeutics Inc. stock pricePhenomenal capital gains - Jammu Links News
How strong is OnKure Therapeutics Inc. company’s balance sheetCapitalize on emerging growth stocks - Jammu Links News
What is the risk reward ratio of investing in OnKure Therapeutics Inc. stockUnlock powerful trading signals for profits - Jammu Links News
When is OnKure Therapeutics Inc. stock expected to show significant growthHigh-profit stock alerts - Jammu Links News
Is OnKure Therapeutics Inc. a good long term investmentInvest smarter with daily stock recommendations - Jammu Links News
What are the technical indicators suggesting about OnKure Therapeutics Inc.Capitalize on market shifts before others do - Jammu Links News
How does OnKure Therapeutics Inc. generate profit in a changing economyCapitalize on emerging market sectors - Jammu Links News
Why is OnKure Therapeutics Inc. stock attracting strong analyst attentionAchieve impressive returns with smart timing - Jammu Links News
Onkure Therapeutics Inc Stock (OKUR) Financials Data
There is no financial data for Onkure Therapeutics Inc (OKUR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Onkure Therapeutics Inc Stock (OKUR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Leverone Jason A. | Chief Financial Officer |
Jun 23 '25 |
Sale |
2.38 |
303 |
722 |
12,906 |
| Cormorant Asset Management, LP | Former 10% Owner |
May 15 '25 |
Sale |
1.85 |
1,813,439 |
3,363,023 |
0 |
| ACORN BIOVENTURES, L.P. | 10% Owner |
May 15 '25 |
Buy |
1.85 |
1,129,730 |
2,090,000 |
1,129,730 |
| ACORN BIOVENTURES, L.P. | 10% Owner |
May 15 '25 |
Buy |
1.85 |
270,270 |
500,000 |
1,709,944 |
| Cormorant Asset Management, LP | 10% Owner |
May 12 '25 |
Sale |
1.99 |
24,300 |
48,236 |
1,813,439 |
| Saccomano Nicholas A | President and CEO |
Apr 07 '25 |
Sale |
2.67 |
516 |
1,378 |
3,682 |
| Saccomano Nicholas A | President and CEO |
Apr 04 '25 |
Sale |
3.33 |
358 |
1,191 |
4,198 |
| Leverone Jason A. | Chief Financial Officer |
Apr 07 '25 |
Sale |
2.67 |
1,844 |
4,925 |
13,209 |
| Leverone Jason A. | Chief Financial Officer |
Apr 04 '25 |
Sale |
3.33 |
1,278 |
4,253 |
15,053 |
| Leonard Braden Michael | 10% Owner |
Sep 25 '24 |
Buy |
1.50 |
68,746 |
102,872 |
3,457,395 |
0.45%
0.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):